Sorry, you need to enable JavaScript to visit this website.
Latest News
May 29, 2020
Not intended for U.S. and UK Media - American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program):
Efficacy of Vitrakvi™ (larotrectinib) further established with continued high response rates and durable response in updated analyses in adult patients and quality of life data in adult and pediatric patients with TRK fusion cancer
May 22, 2020
Not intended for U.S. and UK Media
Bayer submits larotrectinib for marketing authorization in Japan for the treatment of TRK fusion cancer
May 14, 2020
Not intended for U.S. and UK Media
Bayer and ArcherDX to develop next-generation sequencing (NGS)-based companion diagnostic (CDx) for precision oncology treatment Vitrakvi™
May 13, 2020
Not intended for U.S. and UK Media - New ARAMIS Phase III data to be presented at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program
Nubeqa™ (darolutamide) significantly improved overall survival with a favorable safety profile in men with non-metastatic prostate cancer
May 11, 2020
Not intended for U.S. and UK Media
Bayer to Present Data from Growing Oncology Portfolio at the ASCO20 Virtual Scientific Program
Global Health Policy Blog
Current Topics
All